AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections. AmpliPhi Biosciences Corporation has a collaboration agreement and a license agreement with the University of Leicester; and a collaboration agreement with the Western Sydney Local Health District and the Westmead Institute for Medical Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-804-8272524
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees31
OptionableNot Optionable
Ampliphi Biosciences (NYSEAMERICAN:APHB) Frequently Asked Questions
What is Ampliphi Biosciences' stock symbol?
Ampliphi Biosciences trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "APHB."
How were Ampliphi Biosciences' earnings last quarter?
Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) posted its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.02. View Ampliphi Biosciences' Earnings History.
When is Ampliphi Biosciences' next earnings date?
What price target have analysts set for APHB?
1 Wall Street analysts have issued twelve-month price targets for Ampliphi Biosciences' shares. Their predictions range from $4.00 to $4.00. On average, they expect Ampliphi Biosciences' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 1,438.5% from the stock's current price. View Analyst Price Targets for Ampliphi Biosciences.
What is the consensus analysts' recommendation for Ampliphi Biosciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ampliphi Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ampliphi Biosciences.
Has Ampliphi Biosciences been receiving favorable news coverage?
News headlines about APHB stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ampliphi Biosciences earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the next few days.
Are investors shorting Ampliphi Biosciences?
Ampliphi Biosciences saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 375,055 shares, a decline of 22.4% from the December 31st total of 483,345 shares. Based on an average trading volume of 647,303 shares, the short-interest ratio is currently 0.6 days. Currently, 1.2% of the shares of the company are sold short. View Ampliphi Biosciences' Current Options Chain.
Who are some of Ampliphi Biosciences' key competitors?
Some companies that are related to Ampliphi Biosciences include Navidea Biopharmaceuticals (NAVB), Ceapro (CZO), Galena Biopharma (SLS), Nuvo Pharmaceuticals (NRI), Novoheart (NVH), Acrux (ACR), biOasis Technologies (BTI), Oragenics (OGEN), NovaBay Pharmaceuticals (NBY), Quest PharmaTech (QPT), Altimmune (ALT), Medicenna Therapeutics (MDNA), Trillium Therapeutics (TRIL), CAN-FITE BIOPHA/S (CANF) and Rhinomed (RNO).
Who are Ampliphi Biosciences' key executives?
Ampliphi Biosciences' management team includes the folowing people:
- Dr. Paul C. Grint, CEO & Director (Age 61)
- Mr. Steven R. Martin, Sr. VP & CFO (Age 58)
- Mr. Michael Scott Salka, Consultant (Age 57)
- Dr. Alexander Gaidamaka, VP of Chemistry, Manufacturing & Control
- Dr. Sandra Morales, VP of Research
How do I buy shares of Ampliphi Biosciences?
Shares of APHB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ampliphi Biosciences' stock price today?
One share of APHB stock can currently be purchased for approximately $0.26.
How big of a company is Ampliphi Biosciences?
Ampliphi Biosciences has a market capitalization of $8.40 million. Ampliphi Biosciences employs 31 workers across the globe.
What is Ampliphi Biosciences' official website?
How can I contact Ampliphi Biosciences?
Ampliphi Biosciences' mailing address is 3579 Valley Centre Drive, SAN DIEGO, CA 92130, United States. The biotechnology company can be reached via phone at +1-804-8272524.
MarketBeat Community Rating for Ampliphi Biosciences (NYSEAMERICAN APHB)
MarketBeat's community ratings are surveys of what our community members think about Ampliphi Biosciences and other stocks. Vote "Outperform" if you believe APHB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APHB will underperform the S&P 500 over the long term. You may vote once every thirty days.
